Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR – Get Rating)’s share price passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $6.86 and traded as low as $4.10. Eiger BioPharmaceuticals shares last traded at $4.11, with a volume of 173,324 shares traded.
Analyst Upgrades and Downgrades
A number of research analysts have issued reports on EIGR shares. StockNews.com lowered shares of Eiger BioPharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, November 4th. BTIG Research reduced their target price on shares of Eiger BioPharmaceuticals from $57.00 to $48.00 and set a “buy” rating on the stock in a report on Wednesday, September 7th.
Eiger BioPharmaceuticals Stock Performance
The company has a market capitalization of $181.13 million, a PE ratio of -1.71 and a beta of 1.44. The company has a debt-to-equity ratio of 0.50, a quick ratio of 5.34 and a current ratio of 5.45. The stock’s fifty day simple moving average is $5.63 and its 200-day simple moving average is $6.86.
Institutional Inflows and Outflows
About Eiger BioPharmaceuticals
Eiger BioPharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection.
- Get a free copy of the StockNews.com research report on Eiger BioPharmaceuticals (EIGR)
- Is the 60/40 Portfolio Mix Still in Vogue?
- Institutional Support for Analog Devices Remains High
- Three CBD Stocks to Dominate a Budding Industry
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Microsoft Shares: Is it Time to Back Up the Truck?
Receive News & Ratings for Eiger BioPharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger BioPharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.